3 CDMO Stocks With a Strong Future Roadmap: Divi's Laboratories, Laurus Labs and Neuland Laboratories

CDMO stocks give investors exposure to global drug makers outsourcing the making of active ingredients to India. Results depend on customer orders, capacity and margins, which is why client relationships and quality records matter as much as headline growth.

This list covers three API and CDMO stocks: Divi's Laboratories for generic APIs and custom synthesis for global pharma companies, Laurus Labs for APIs, formulations and a growing CDMO business and Neuland Laboratories for complex generic APIs and custom manufacturing. Every figure comes from the latest reported financials and the 5 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are CDMO Stocks?

CDMO stocks are shares of companies that develop and make active pharmaceutical ingredients and finished drugs for other pharma companies. Results depend on innovator customers, generic APIs, custom synthesis and plant capacity, so quality records and long customer ties separate the stronger names.

CDMO Stocks at a Glance

The table compares size, valuation, return on equity and debt for the three CDMO stocks as of the 5 October 2026 close.

Among API and CDMO stocks, all three trade at a premium to their industry P/E multiples.

Why Do CDMO Stocks Have a Strong Roadmap in India?

CDMO stocks have a strong roadmap in India because global drug makers want a second source beyond China, India has a deep chemistry base and makers are adding capacity. Three drivers stand out.

• China plus one: Global customers add Indian suppliers to reduce reliance on one country.
• Custom synthesis: Long-term contracts with innovator companies give steady, higher-margin work.
• Capacity expansion: New plants let makers take larger orders and widen their range.

Divi's Laboratories: Custom Synthesis and Generic APIs Anchor the Roadmap

Divi's Labs' roadmap rests on custom synthesis for innovator customers, a strong position in generic APIs and new capacity at its large manufacturing sites.

Revenue grew from Rs 9,073.70 crore in FY22 to Rs 11,067.00 crore in FY26, a 22.0% rise, and FY26 revenue was 14.0% higher than FY25. FY26 net profit rose 17.2% to Rs 2,568.00 crore. Over four years, net profit moved from Rs 2,960.45 crore in FY22 to Rs 2,568.00 crore. In Q1 FY27, revenue grew 24.3% to Rs 3,144.00 crore, and net profit rose 65.5% to Rs 902.00 crore. Operating margin was 36.70% in FY26 and 42.82% in Q1 FY27 against 35.19% a year earlier.

Debt to equity is 0.00 and return on equity is 15.32%. FY26 operating cash flow was Rs 2,738.00 crore against capital expenditure of Rs 2,520.00 crore. Divi's Labs paid a dividend of Rs 30 per share for FY26, a yield of 0.33%. At a P/E of 83.62 against an industry P/E of 37.53, the stock trades above its industry multiple.

What to watch: The P/E of 83.62 is more than double the industry multiple of 37.53, and FY26 net profit of Rs 2,568 crore is still below the Rs 2,960.45 crore of FY22. The P/E of 83.62 sits above the industry P/E of 37.53, so earnings delivery matters for the valuation.

Laurus Labs: Contract Manufacturing and New Capacity Drive the Pipeline

Laurus Labs' roadmap rests on a growing contract development and manufacturing business, a wider range of formulations and new capacity in synthesis and biotech.

Revenue grew from Rs 4,950.87 crore in FY22 to Rs 6,867.85 crore in FY26, a 38.7% rise, and FY26 revenue was 22.0% higher than FY25. FY26 net profit rose 151.1% to Rs 889.85 crore. Over four years, net profit rose from Rs 832.43 crore in FY22 to Rs 889.85 crore. In Q1 FY27, revenue grew 28.8% to Rs 2,035.49 crore, and net profit rose 124.7% to Rs 361.99 crore. Operating margin was 26.90% in FY26 and 31.95% in Q1 FY27 against 25.01% a year earlier.

Debt to equity is 0.48 and return on equity is 16.77%. FY26 operating cash flow was Rs 1,623.50 crore against capital expenditure of Rs 1,069.95 crore. Laurus Labs paid a dividend of Rs 2 per share for FY26, a yield of 0.10%. At a P/E of 97.32 against an industry P/E of 37.53, the stock trades above its industry multiple.

What to watch: The P/E of 97.32 is well above the industry multiple of 37.53, and FY26 net profit only just moved above the FY22 level after a dip in FY24 and FY25. The P/E of 97.32 sits above the industry P/E of 37.53, so earnings delivery matters for the valuation.

Neuland Laboratories: Complex APIs and Custom Manufacturing Build the Next Leg

Neuland's roadmap rests on complex generic APIs, custom manufacturing for innovator companies and new capacity that widens its range of molecules.

Revenue grew from Rs 953.15 crore in FY22 to Rs 2,053.15 crore in FY26, a 115.4% rise, and FY26 revenue was 37.1% higher than FY25. FY26 net profit rose 39.9% to Rs 364.00 crore. Over four years, net profit rose from Rs 63.82 crore in FY22 to Rs 364.00 crore. In Q1 FY27, revenue grew 116.3% to Rs 650.07 crore, and net profit rose from Rs 13.90 crore to Rs 147.67 crore. Operating margin was 29.89% in FY26 and 36.06% in Q1 FY27 against 14.46% a year earlier.

Debt to equity is 0.16 and return on equity is 19.42%. FY26 operating cash flow was Rs 346.68 crore against capital expenditure of Rs 397.13 crore. Neuland Laboratories paid a dividend of Rs 34 per share for FY26, a yield of 0.16%. At a P/E of 56.34 against an industry P/E of 37.53, the stock trades above its industry multiple.

What to watch: Quarterly revenue is lumpy, with Rs 788.71 crore in Q4 FY26 against Rs 300.61 crore in Q1 FY26, and FY26 capital expenditure of Rs 397.13 crore exceeded operating cash flow. The P/E of 56.34 sits above the industry P/E of 37.53, so earnings delivery matters for the valuation.

Best CDMO Stocks in India: Divi's Labs vs Laurus Labs vs Neuland Laboratories on Key Financials

Among the best CDMO stocks in India, Divi's Labs leads on FY26 operating margin; Neuland Laboratories leads on Q1 FY27 revenue growth and five-year revenue growth. The table puts the numbers side by side.

CDMO revenue can be lumpy with customer orders, so full-year trends say more than one quarter.

How to Evaluate Pharma Contract Manufacturing Stocks to Buy Before You Invest

A short checklist keeps the research consistent when you screen CDMO stocks and shortlist pharma contract manufacturing stocks to buy.

1. Compare each stock's P/E with its industry P/E, which is 37.53 for all three here.
2. Track operating margin across several quarters, because input costs can move faster than prices.
3. Check whether revenue growth is turning into profit growth, not only sales.
4. Read operating cash flow against capital expenditure to see how growth is funded.
5. Watch debt to equity and interest cover before sizing a position.
6. Spread exposure across companies and business lines instead of one demand cycle.

Check the Univest Screener for live data on these CDMO stocks

Risks to Consider Before Investing in CDMO Stocks

• Valuation: Divi's Labs trades at 83.62 times earnings and Laurus Labs at 97.32, against an industry multiple of 37.53, so any slowdown can weigh on the stocks.
• Customer concentration: A few large customers drive a big share of orders, so a delay or loss matters.
• Regulatory checks: Inspection findings at a plant can disrupt supplies.
• Heavy investment: New capacity needs large capital, as seen in Divi's Labs and Neuland capital expenditure.

Download the Univest iOS App or Univest Android App to track Divi's Labs, Laurus Labs and Neuland Laboratories live.

Final Take: Which Stock Has the Strongest Roadmap?

These three pharma contract manufacturing stocks cover custom synthesis and generic APIs, APIs with a growing CDMO arm, and complex APIs with custom manufacturing. Divi's Labs leads on FY26 operating margin; Neuland Laboratories leads on Q1 FY27 revenue growth and five-year revenue growth.

Across API and CDMO stocks, each roadmap still has to turn growth into steady profit, so independent research and position sizing matter. Investors should consult a SEBI-registered advisor before acting on any of the pharma contract manufacturing stocks to buy discussed here.

FAQs on CDMO Stocks

Which are the best CDMO stocks in India with a strong roadmap?

Ans. Divi's Laboratories, Laurus Labs and Neuland Laboratories stand out for their roadmaps in APIs and contract manufacturing. FY26 revenue growth was 14.0% at Divi's Labs, 22.0% at Laurus Labs and 37.1% at Neuland Laboratories, and return on equity ranges from 15.32% to 19.42%.

Is Divi's Laboratories a good stock to buy now?

Ans. Divi's Laboratories has a debt to equity ratio of 0.00, a return on equity of 15.32% and a P/E of 83.62 against an industry P/E of 37.53. Customer orders, regulatory checks and capital spending move results, and the stock trades above its industry multiple. This article is not investment advice, so consult a SEBI-registered advisor before deciding.

What is the P/E ratio of Divi's Labs, Laurus Labs and Neuland Laboratories?

Ans. The P/E ratio is 83.62 for Divi's Labs (industry 37.53), 97.32 for Laurus Labs (industry 37.53) and 56.34 for Neuland Laboratories (industry 37.53). All three trade at or above the industry multiple.

Which of these CDMO stocks has the highest return on equity?

Ans. Neuland Laboratories has the highest return on equity at 19.42%, followed by Laurus Labs at 16.77% and Divi's Laboratories at 15.32%.

What are the risks of investing in CDMO stocks?

Ans. The main risks are very high valuations, dependence on a few customers, regulatory inspections and heavy capital spending. Divi's Labs trades at 83.62 times earnings and Laurus Labs at 97.32, against an industry multiple of 37.53.

How did Divi's Labs, Laurus Labs and Neuland Laboratories perform in Q1 FY27?

Ans. Divi's Laboratories reported revenue of Rs 3,144.00 crore, up 24.3% year on year, and net profit rose 65.5% to Rs 902.00 crore. Laurus Labs reported revenue of Rs 2,035.49 crore, up 28.8% year on year, and net profit rose 124.7% to Rs 361.99 crore. Neuland Laboratories reported revenue of Rs 650.07 crore, up 116.3% year on year, and net profit rose from Rs 13.90 crore to Rs 147.67 crore.

Do CDMO stocks pay dividends?

Ans. Yes, all three companies pay dividends. The dividend yield is 0.33% for Divi's Labs, 0.10% for Laurus Labs and 0.16% for Neuland Laboratories, based on dividends declared for FY26.

How can I invest in CDMO stocks in India?

Ans. You can buy CDMO stocks through a demat and trading account on NSE or BSE after checking each company's financials, margins and valuation. The Univest Screener lets you compare fundamentals before placing an order. Investments in securities are subject to market risk, so consider your risk profile first.